Bayer making compound for incubator client; Investment will help Azelis go global;

> Bayer HealthCare will handle the preclinical manufacturing of a compound for Aronora, a tenant of Bayer's U.S. CoLaborator incubator facility in San Francisco. Release

> Apax Partners will buy a majority stake in Azelis from 3i Group for an undisclosed sum, an investment that will help the European chemical distributor expand globally. Story

> A German team says continuous manufacturing could lower the cost of making the API efaverinz used in an HIV drug. Report

Suggested Articles

Eli Lilly has a pipeline stuffed with a host of assets and has decided it needs a new injectable drug and device plant to manufacture some of them.

The $520 million investment includes $230 million for AZ's Dunkirk, France manufacturing site dedicated to inhalers and $275 million for R&D.

Manufacturing issues have caused GlaxoSmithKline to halt production and distribution of Excedrin, which has led to outages at some pharmacies.